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Abstract
Background: The prognostic significance of tumor-associated macrophages (TAM) in adult classical Hodgkin
lymphoma (cHL) remains controversial. Here, we report a meta-analysis of the association of CD68 and CD163
infiltration on the clinical outcome of adult cHL.
Methods: A comprehensive search to identify relevant articles was performed in PubMed, Embase, and Google
Scholar on January 31, 2016. Using the fixed effect or random effects model of DerSimonian and Laird, hazard
ratios (HR) or odds ratios (OR) with 95 % confidence intervals (CIs) were used as the effect size estimate.
Results: Twenty-two eligible studies with a total of 2959 patients were identified. Our analysis indicated that a
high density of CD68+ TAMs in the tumor microenvironment of adult cHL predicted poor overall survival
(OS) (HR: 2.41; 95 % CI, 1.92–3.03), shorter progression-free survival (PFS) (HR: 1.78; 95 % CI, 1.45–2.18),
and poor disease-specific survival (HR: 2.71; 95 % CI, 1.38–5.29). High density of CD163+ TAMs in the tumor
microenvironment of adult cHL also predicted poor OS (HR: 2.75; 95 % CI, 1.58–4.78) and poor PFS
(HR: 1.66; 95 % CI, 1.22–2.27). In addition, we demonstrated that a high density of either CD68+ or
CD163+ TAMs was associated with the presence of Epstein-Barr virus in neoplastic cells (ORCD68: 3.13;
95 % CI, 2.02–4.84; ORCD163: 2.88; 95 % CI, 1.55–5.34). A high density of either CD68
+ or CD163+ TAMs
tend to be associated with a more advanced clinical stage (ORCD68: 1.25; 95 % CI, 0.93–1.67; OR CD163:
1.19; 95 % CI, 0.86–1.63), B-symptoms (ORCD68: 1.35; 95 % CI, 0.90–2.01; ORCD163: 2.19; 95 % CI, 0.96–5.03),
higher International Prognostic Factors Project Score (ORCD68: 1.20; 95 % CI, 0.67–2.15; ORCD163: 2.00;
95 % CI, 0.92–4.35), and bulky disease (ORCD68: 1.47; 95 % CI, 0.88–2.47; ORCD163: 1.19; 95 % CI, 0.72–1.96).
Conclusions: Our analyses suggest that a high density of either CD68+ or CD163+ TAMs is a robust predictor
of adverse outcomes in adult cHL. Increased TAMs should be taken into account to further improve
prognostic stratification and the planning of appropriate therapeutic strategies.
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Background
Classical Hodgkin lymphoma (cHL) carries an excellent
prognosis for most patients, with more than 80 % of
patients experiencing long-term remission following
conventional chemotherapy or radiotherapy-based pro-
tocols [1–3]. However, approximately 20 % of patients
experience relapse or disease that is refractory to all
conventional therapies, and many patients may suffer
short- and long-term treatment-related complications
[4–6]. The International Prognostic Factors Project
Score (IPS) is the most widely used prognostic system;
however, it is rarely employed to modify treatment [7, 8].
Robust prognostic indicators are thus needed to better
risk-stratify patients at diagnosis.
cHL is unique among the lymphomas because malig-
nant cells are heavily outnumbered by reactive cells in
the tumor microenvironment, such as macrophages, T
cells, B cells, eosinophils, mast cells, and other stromal
elements. In an adult cHL microenvironment, malignant
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Hodgkin-Reed-Sternberg cells express a variety of cyto-
kines and chemokines. This is thought to be the driving
force behind an abnormal immune response, perpetu-
ated by additional factors secreted by recruited reactive
cells in the microenvironment [9]. Steidl et al. [10]
were the first to show, by gene expression profiling
followed by immunohistochemistry assay, that the
quantity of tumor-associated macrophages (TAMs) pre-
dicts progression-free survival (PFS). However, most stud-
ies that used various antibodies to stain TAMs were
inconclusive regarding the association of CD68+ and
CD163+ TAM density and survival. Some studies have
indicated that a high density of either CD68+ or CD163+
TAMs in the tumor microenvironment of adult cHL is
associated with poorer outcomes [10–22]. Other studies
have not confirmed this finding [23–31], and using
TAMs as a biomarker to risk-stratify patients remains
controversial.
The objective of this study was to evaluate the prog-
nostic significance of elevated density of CD68+ and
CD163+ TAMs in the tumor microenvironment on over-
all survival (OS) and PFS in patients with adult cHL. In
addition, the relationship between CD68+ and CD163+
TAMs in the tumor microenvironment of adult cHL and
other clinical characteristics was also examined.
Methods
The present meta-analysis was performed in accordance
with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses Statement [32].
Literature search
We performed a systematic electronic search in
PubMed, Embase, and Google scholar for articles pub-
lished before January 31, 2016. We identified studies by
using Medical Subject Heading (MeSH) terms and
corresponding keywords, including “macrophages”, “tumor-
associated macrophage”, “tumor-infiltrating macrophage”,
“intratumoral macrophage”, “TAMs”, “Hodgkin disease”,
“classical Hodgkin lymphoma”. No language restriction was
applied. We also manually checked the bibliographies of
previous reviews and references in all selected studies.
Investigators were contacted and asked to supply additional
data when key information relevant to the meta-analysis
was missing.
Selection criteria
Studies were included if they (1) were prospective or
retrospective cohort studies or clinical trials; (2) contained
immunochemistry data used to evaluate TAM by anti-
CD68 or anti-CD163; (3) were studies that involved
patients with a proven diagnosis of cHL performed to
investigate the correlation of CD68+ and CD163+
TAM density and survival; or (4) tumor-associated
macrophages in adult cHL were described as high
(above the cut-off value) and low (below the cut-off value)
density. Studies were excluded if they were (1) review
articles, case reports, animal or in vitro studies; or (2)
analyzing pediatric patients or serum CD68 or CD163
samples.
Study selection, data extraction, and end points
Two investigators (BPG and HC) independently selected
articles and extracted data from eligible studies. Disagree-
ments were resolved by consensus. Baseline characteristics
and outcomes were extracted from the selected articles.
Information taken from each study included the name of
the first author, year of publication, country, number of
patients, stage, sex, treatment, WHO subtype, Epstein-
Barr virus (EBV) status, antibodies, thresholds, median
follow-up, and outcome correlation. In situ hybridization
(ISH) analysis for EBV-encoded RNA (EBER) was per-
formed in all included studies. Among the included
studies, there were six studies using a follow-up time of
less than 5 years [13, 16, 23, 26, 27, 29]. We chose
OS and PFS as endpoints for our meta-analysis. Various
endpoints for PFS were reported in the selected studies,
including event-free survival (EFS [12, 14, 18, 19, 22])
and failure-free survival (FFS) [15]. As PFS, EFS, and
FFS had a similar definition in these articles, we ope-
rationally defined PFS to include EFS or FFS for studies
that did not provide PFS.
Quality assessment
The Newcastle-Ottawa Scale (NOS) was used to assess
the quality of each individual study; this was performed
independently by two authors (BPG and XHT). The
NOS comprises three quality parameters: selection
(0–4 points), comparability (0–2 points), and outcome
assessment (0–3 points). Studies with NOS scores
of ≥ 6 were determined to be high-quality [33].
Statistical analysis
The primary outcome was survival in patients with a
high density of either CD68+ or CD163+ TAMs com-
pared to those with a low density of CD68+ or CD163+
TAMs. The cut-off value for “high versus low” CD68+ or
CD163+ TAM density was determined by the investiga-
tors in each study. Hazard ratios (HRs) with 95 % confi-
dence intervals (CIs) were combined to obtain an
effective value. For studies in which HRs and CIs were
not available, we used the method proposed by Parmar
et al. [34] to derive estimates from survival curves. An
HR > 1 indicated poor survival in the group with high
CD68+ or CD163+ TAM density.
For the pooled analysis of the relationship between
high CD68+ or CD163+ TAM density and EBV status or
other clinical parameters (such as stage), odds ratios
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(OR) and their 95 % CIs were combined to give the
effective value. An OR > 1 indicated a higher probability
that EBV was present and advanced stage in the group
with high CD68+ or CD163+ TAM density. The point
estimate of the HR or OR was considered statistically
significant at the P < 0.05 level if the 95 % CI did not
include the value 1. Heterogeneity was assessed by the
χ2 test and expressed as I2 index [35], which describes
the percentage of total variation across studies due to
heterogeneity rather than chance (25 % low heteroge-
neity, 50 % medium, 75 % high). If heterogeneity existed
between primary studies, a random effects model was
used. Otherwise, a fixed effects model was used in meta-
analysis [36]. If results of both univariate and multiva-
riate Cox regression analyses were reported, multivariate
models were used for a more accurate estimate of the ef-
fect of CD68 or CD163 expression. Begg’s test [37] and
Egger’s test [38] were used to detect possible publication
bias. All analyses were carried out using STATA statis-
tical software package version 12.0 (STATA, College
Station, TX).
Results
Selection and characteristics of studies
Our initial search yielded 1585 articles. After removing
duplicates and screening the titles and abstracts, 31
articles were reviewed in further detail. After reviewing
the full text, 22 unique studies were selected as poten-
tially appropriate for inclusion in the meta-analysis
[10–31]. Our search strategy is presented in Fig. 1.
The main characteristics of the included studies are
summarized in Table 1. Sixteen studies were retrospec-
tive cohorts and six were prospective cohorts. Studies
were published between 2010 and 2016. The studies
were conducted in 12 countries (Denmark, Italy,
Switzerland, France, Spain, Israel, United Kingdom,
Canada, United States, Japan, South Korea, Egypt, India,
Serbia, and China). Population sizes ranged from 61 to
288, with a total of 2959 patients. The reported median
or mean age ranged from 21 to 54 years across eligible
studies.
The points of study quality assessed on the NOS for
assessing quality ranged from 3 to 9 (mean = 6.23), with
higher values indicating better methodology. Certainly,
the low quality studies were also included in the ana-
lyses. The results of this quality assessment are shown
in Table 2.
Prognostic significance of CD68+ TAMs
Fifteen studies were included in the analysis of CD68+
TAMs on OS in adult cHL. The results of our meta-
analysis showed that a high CD68+ TAM density was
associated with shorter OS than a low CD68+ TAM
density, with a pooled HR of 2.41 (95 % CI, 1.92–3.03).
No significant heterogeneity was found across the stu-
dies (I2 = 12.7 %, P = 0.31). Twelve studies reported data
on CD68+ TAMs and PFS in adult cHL. Meta-analyses
results demonstrated that a high CD68+ TAM density
was associated with shorter PFS than a low CD68+ TAM
density, with a pooled HR of 1.78 (95 % CI, 1.45–2.18).
No significant heterogeneity was found across the stu-
dies (I2 = 3.4 %, P = 0.41). HRs for disease-specific sur-
vival (DSS) were available in four studies. The estimated
pooled HR showed that a high CD68+ TAM density was
associated with poorer DSS than a low CD68+ TAM
density, with a pooled HR of 2.71 (95 % CI, 1.38–5.29).
No significant heterogeneity was found across the stu-
dies (I2 = 0.0 %, P = 0.73; Fig. 2).
Prognostic significance of CD163+ TAMs
Meta-analysis of seven studies showed poorer OS in the
high CD163+ TAM density group than in the low
CD163+ TAM density group, with a pooled HR of 2.75
(95 % CI, 1.58–4.78). There was an indication of
medium heterogeneity across the studies, but it did not
reach statistical significance (I2 = 51.8 %, P = 0.053). HRs
for PFS were available in five studies with adult classical
Hodgkin lymphoma. The results of our meta-analysis
showed that high CD163+ TAM density was associated
with shorter PFS than low CD163+ TAM density, with a
pooled HR of 1.66 (95 % CI, 1.22–2.27). No significant
heterogeneity was found across the studies (I2 = 12.6 %,
P = 0.11; Fig. 3). Notably, only one study provided
Fig. 1 Flow diagram of the systematic review and meta-analysis process
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Table 1 Characteristics of studies included in the meta-analysis
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Table 1 Characteristics of studies included in the meta-analysis (Continued)
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ABVD doxorubicin, bleomycin, vinblastine, and dacarbazine, BEACOPP bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, COPP cyclophosphamide, vincristine,
procarbazine, and prednisone, C-MOPP cyclophosphamide, vincristine, procarbazine, prednisone, EVAP etoposide, vinblastine, adriamycin and prednisolone, EBVP epirubicin, bleomycin, vinblastine and prednisone,
MOPP mustargen, oncovin, procarbazine, and prednisone, RT radiotherapy, Stanford V vinblastine, doxorubicin, vincristine, bleomycin, mustard, etoposide, and prednisone, NS nodular sclerosis, MC mixed cellularity,
Neg negative, Pos positive, RT radiotherapy, NOS not otherwise specified, PFS progression-free survival, DSS disease-specific survival, EFS event-free survival, OS overall survival, FFS failure-free survival, FFTF freedom













relevant data on the correlation of CD163+ TAMs with
DSS; therefore, the pooled analysis could not be performed.
CD68+ and CD163+ TAMs and clinical features
Meta-analysis of five studies showed a high CD68+ TAM
density was associated with the presence of EBV, with a
pooled OR of 3.13 (95 % CI, 2.02–4.84). There was an
indication of slight heterogeneity across the studies, but it
did not reach statistical significance (I2 = 37.8 %, P = 0.17).
The results of meta-analysis of the four studies showed a
correlation between high CD163+ TAM density and the
presence of EBV. Because significant heterogeneity was
found across the studies (I2 = 67.9 %, P = 0.03), a pooled
OR of 2.88 (95 % CI, 1.55–5.34) was calculated on the
basis of a random-effects model (Fig. 4a).
Ten studies reported data on CD68+ TAMs and Ann
Arbor stage in adult cHL. Meta-analysis of these studies
found a trend for a correlation between high CD68+
TAM density and advanced stage, with a pooled OR of
1.25 (95 % CI, 0.93–1.67). No significant heterogeneity
was found across the studies (I2 = 23.6 %, P = 0.23). Four
studies reported data on CD163+ TAMs and Ann Arbor
stage in adult cHL. Meta-analysis of the four studies
showed a trend for a correlation between high CD163+
TAM density and advanced stage, with a pooled OR of
1.19 (95 % CI, 0.86–1.63). No significant heterogeneity
was found across the studies (I2 = 0.0 %, P = 0.91;
Fig. 4b).
Six studies reported data on CD68+ TAMs and B-
symptoms in adult cHL. The result of meta-analysis of the
six studies showed a trend for a correlation between a
high CD68+ TAM density and B-symptoms, with a pooled
OR of 1.35 (95 % CI, 0.90–2.01). No significant heteroge-
neity was found across the studies (I2 = 23.7 %, P = 0.26).
Two studies reported data on CD163+ TAMs and B-
symptoms in cHL. The result of meta-analysis of the two
studies showed a trend for a correlation between high
CD163+ TAM density and B-symptoms, with a pooled OR
of 2.19 (95 % CI, 0.96–5.03). No significant heterogeneity
was found across the studies (I2 = 57.1 %, P = 0.12; Fig. 4c).
Five studies reported data on CD68+ TAMs and IPS in
adult cHL. The result of meta-analysis of the five studies
Table 2 Assessment of the risk of bias in each cohort study using the Newcastle–Ottawa scale
Study Selection (0–4) Comparability (0–2) Outcome (0–3) Total
REC SNEC AE DO SC AF AO FU AFU
Steidl et al. [10] 1 1 1 1 1 1 1 1 1 9
Tzankov et al. [11] 1 1 1 1 0 0 0 1 1 6
Kamper et al. [12] 1 1 1 1 1 1 1 1 0 8
Hohaus et al. [13] 1 1 1 1 0 0 1 0 0 5
Zaki et al. [23] 0 1 1 1 0 0 0 1 0 4
Azambuja et al. [24] 1 1 1 1 1 1 1 1 0 8
Yoon et al. [14] 1 1 1 1 1 0 1 1 1 8
Tan et al. [15] 1 1 1 1 1 1 1 1 1 9
Sanchez-Espiridion et al. [31] 0 1 1 1 0 0 0 1 0 4
Abdou et al. [16] 0 1 1 1 0 0 0 0 0 3
Greaves et al. [17] 1 1 1 1 1 1 1 1 1 9
Deau et al. [25] 0 1 1 1 0 0 0 1 0 4
Panico et al. [26] 1 1 1 1 0 0 1 1 0 6
Casulo et al. [18] 1 1 1 1 1 0 1 1 0 7
Koh et al. [19] 1 1 1 1 0 0 1 1 0 6
Ping et al. [27] 0 1 1 1 0 0 1 1 0 5
Klein et al. [28] 0 1 1 1 0 0 1 1 1 6
Touati et al. [20] 1 1 1 1 0 0 0 1 1 6
Kayal et al. [30] 1 1 1 1 0 0 1 1 0 6
Agur et al. [29] 1 1 1 1 0 0 1 1 1 7
Moreno et al. [21] 0 1 1 1 0 0 1 1 0 5
Jakovic et al. [22] 1 1 1 1 0 1 0 1 0 6
“1” indicates that the study has satisfied the item and “0” indications the opposite
REC representativeness of the exposed cohort, SNEC selection of the non-exposed cohort, AE ascertainment of exposure, DO demonstration that outcome of
interest was not present at start of study, SC study controls for age, sex, AF study controls for any additional factors (Chemotherapy, radiotherapy), AO assessment
of outcome, FU follow-up long enough (36 M) for outcomes to occur, AFU adequacy of follow-up of cohorts (≥90 %)
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showed a trend correlation between a high CD68+ TAM
density and higher IPS, with a pooled OR of 1.20
(95 % CI, 0.67–2.15). Three studies reported data on
CD163+ TAM density and IPS in adult cHL. The result of
meta-analysis of the three studies showed a trend for a
correlation between high CD163+ TAM density and a
higher IPS, with a pooled OR of 2.00 (95 % CI, 0.92–4.35).
Significant heterogeneity was found across the studies
(I2 = 62.0 % for CD68+ TAMs and I2 = 72.5 % for
CD163+ TAMs, all P < 0.05; Fig. 4d).
Five studies reported data on CD68+ TAMs and bulky
disease in adult cHL; meta-analysis revealed a trend
correlation between a high CD68+ TAM density and bulky
disease, with a pooled OR of 1.47 (95 % CI, 0.88–2.47).
Two studies reported data on CD163+ TAMs and bulky
disease in adult cHL. The result of meta-analysis of the
two studies showed a trend for a correlation between a
high CD163+ TAM density and bulky disease, with a
pooled OR of 1.19 (95 % CI, 0.72–1.96). No significant
heterogeneity was found across the studies (I2 = 40.4 % for
CD68+ TAM density and I2 = 0.0 % for CD163 expression,
all P > 0.10; Fig. 4e).
Publication bias
A more formal evaluation of CD68+ TAMs using Begg’s
and Egger’s tests showed no evidence of significant
publication bias (OS, Begg’s test P = 0.488; Egger’s test
P = 0.522; shown in Fig. 5a; PFS, Begg’s test P = 0.732;
Egger’s test P = 0.639; shown in Fig. 5b). For CD163+
TAMs, there was no evidence for significant publication
bias (OS, Begg’s test P = 0.230; Egger’s test P = 0.172
(Fig. 5c); PFS, Begg’s test P = 1.000; Egger’s test P = 0.356
(Fig. 5d)).
Discussion
Many recent studies have focused on the impact of
non-neoplastic cells on disease pathobiology, specifically
immunohistochemical typing of cells in the microenviron-
ment, with the goal of identifying potential prognostic
markers and therapeutic targets in adult cHL. Due to
Fig. 2 Meta-analysis of the hazard ratios for progression-free survival, disease-specific survival, and overall survival for a high versus a low CD68+
tumor-associated macrophage (TAM) density. Hazard ratios (HRs) and 95 % confidence intervals (CIs) from individual studies are depicted as squares
and horizontal lines, respectively. The pooled estimate is shown as a diamond shape, where the center represents the pooled HRs and the horizontal
borders represent the 95 % CI. HRs are defined as high CD68+ versus low CD68+ TAM density; therefore, a hazard ratio > 1 represents a higher risk of
death or progression associated with a high CD68+ TAM density
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Fig. 3 Meta-analysis of the hazard ratios for progression-free survival and overall survival for high CD163+ versus low CD163+ tumor-associated
macrophage (TAM) density. Hazard ratios and 95 % confidence intervals for death or progression associated with high versus low CD163+ TAM density
Fig. 4 Meta-analysis of the association between CD68+ and CD163+ tumor-associated macrophage (TAM) density and clinical features. The Forest plots
show (a) the association between a high CD68+ and CD163+ TAM density and presence of Epstein-Barr virus of adult classical Hodgkin lymphoma (cHL);
(b) the association between a high CD68+ and CD163+ TAM density and presence of Ann Arbor stage of adult cHL; (c) the association between a high
CD68+ and CD163+ TAM density and B-symptoms of adult cHL; (d) the association between a high CD68+ and CD163+ TAM density and International
Prognostic Factors Project Score of adult cHL; and (e) the association between a high CD68+ and CD163+ TAM density and bulky disease of adult cHL
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flawed statistical analyses and an inability to validate find-
ings, few biomarkers have translated into clinical practice.
Meta-analysis is a valuable tool in biomarker validation;
thus, in this study, we carried out a meta-analysis to
examine the correlation between TAMs and adult cHL
prognosis.
This is the first meta-analysis investigating survival of
cHL patients in which the survival of patients with high
and low density of CD68+ and CD163+ TAMs was com-
pared. Our results demonstrated that a high density of
either CD68+ or CD163+ TAMs in the tumor micro-
environment significantly predicted poor OS and shorter
PFS for adult cHL (P = 0.000 and P = 0.000, respectively).
A high CD68+ TAM density was associated with worse
DSS than that in the group with a low CD68+ TAM
density (P = 0.004). Furthermore, we also conducted a
pooled analysis on the correlation between macrophage-
associated markers and adult cHL EBV positivity. This
finding suggests that a high density of either CD68+ or
CD163+ TAMs is strongly correlated with EBV positivity
(P = 0.000 and P = 0.001, respectively). In addition, these
results suggested a trend towards a high density of
both CD68+ and CD163+ TAMs with the presence of
B-symptoms, advanced stage, bulky disease, and an IPS
greater than 3; however, these results were not statistically
significant. Taken together, the results of our pooled
analysis support that a higher density of either CD68+ or
CD163+ TAMs in the tumor microenvironment of adult
cHL is associated with a higher risk of worst outcome.
The results of our meta-analysis indicate an asso-
ciation between increased density of both CD68+ and
CD163+ TAMs in the tumor microenvironment of adult
cHL and poor outcome. Among the included studies,
different score methods and threshold values were used
in the measurement of CD68+ and CD163+ TAMs using
immunohistochemistry. Most of the studies used manual
visual scoring techniques, ranging from cell counting
[11, 23, 24] to computer-assisted methods of point
counting [12, 21] and image analysis [15, 17]. The lack
of consistent and reproducible of thresholds in these
studies made it difficult to separate patients into low-
and high-risk populations. Reproducibility of data pro-
duced in different laboratories and of assay methods for
tissue sections will need to be a focus of future studies.
Few biomarkers have translated into clinical practice
since the reproducibility of immunohistochemical scoring
has been suggested as a reason for inconclusive results,
and thus more robust multigene predictors have been
reported based on expression profiling [10]. However,
these gene expression studies were limited by small case
numbers and the lack of available clinical data.
In addition, the antibody used to stain macrophages
varied. It has been reported that the KP1 clone does not
only react specifically with macrophages, but also reacts
with myeloid and fibroblastic cells [39]. The clone 10D6
for CD163 is more specific for macrophages than either
the KP1 or PGM1 clones for CD68 [40]. Thus, CD163
may be a better marker for TAMs than CD68. When
Fig. 5 Begg’s funnel plot showed no publication bias among the included studies. a CD68+ tumor-associated macrophages (TAMs) and overall
survival OS (P = 0.488). b CD68+ TAMs and PFS (P = 0.732). c CD163+ TAMs and OS (P = 0.230). d CD163+ TAMs and PFS (P = 1.000)
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antibodies to CD68 and CD163 have both been used,
some studies have noted discrepancies in the association
of macrophages with patient outcomes. Martin-Moreno
et al. [21] observed an association between increased
CD68-stained cells and DSS in a cohort, but no asso-
ciation was observed using an antibody against CD163.
In contrast, Zaki et al. [23] and Klein et al. [28] only saw
an association between CD163 and outcome. Some
studies indicate that TAMs in adult cHL promote
tumor growth and angiogenesis, suppression of adap-
tive immune responses, and contribute to immune
evasion by tumor cells, and thus may be associated
with poor prognosis [41–44].
These analyses have some advantages and important
implications. First, study quality scores, assessed using
the NOS, had a mean score of 6.23, giving validity to the
results of the present meta-analysis. Second, Egger’s test
did not detect publication bias, indicating that the re-
sults are not biased. Third, this study shows that a high
density of both CD68+ and CD163+ TAMs is associated
with poorer outcome, which suggests that the TAMs
may be useful as a drug therapeutic target. Fourth, our
study identifies a subgroup of adult cHL tumors with
poorer outcome. Finally, it highlights the importance of
the development of an accurate biomarker for assess-
ment of adult cHL.
The meta-analysis performed in this study had several
limitations. First, negative studies are less frequently
published, or are published with less detailed results,
making them less assessable, potentially leading to some
bias. Second, our meta-analysis is based on data from
trials from which the results have been published, and
we did not obtain updated individual patient data. Use
of individual patient data may further enhance the
accuracy and reduce the uncertainty of the estimates.
Third, because of the variety of endpoints reported in
adult cHL studies, we operationally defined adult cHL
PFS to include EFS or FFS in studies that did not
provide PFS. Fourth, some of the HRs with 95 % CIs
were extracted from the Kaplan–Meier survival curve.
Finally, among the included studies in the current meta-
analysis, six had a follow-up time of less than 5 years,
which may have incorporated bias.
Conclusions
In conclusion, the results presented here indicate that a
high density of either CD68+ or CD163+ TAMs in the
tumor microenvironment of adult cHL is associated with
poor survival. A high density of both CD68+ and CD163+
TAMs was associated with the presence of EBV in
neoplastic cells, and might provide essential information
for the prediction of advanced stage, B-symptoms, bulky
disease, and higher IPS. Evaluation of TAMs should be
considered in prospective clinical trials, and patients
with increased TAMs may benefit from more intensive
chemotherapy or novel agents designed to disrupt cross-
talk between Hodgkin-Reed-Sternberg cells and benign
macrophages.
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